140 related articles for article (PubMed ID: 7879332)
1. Definitive tumor resection and percutaneous bacille Calmette-Guérin for management of renal pelvic transitional cell carcinoma in solitary kidneys.
Vasavada SP; Streem SB; Novick AC
Urology; 1995 Mar; 45(3):381-6. PubMed ID: 7879332
[TBL] [Abstract][Full Text] [Related]
2. Complications of intracavitary bacillus Calmette-Guerin after percutaneous resection of upper tract transitional cell carcinoma.
Bellman GC; Sweetser P; Smith AD
J Urol; 1994 Jan; 151(1):13-5. PubMed ID: 8254791
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous management of renal pelvic urothelial tumors: long-term followup.
Goel MC; Mahendra V; Roberts JG
J Urol; 2003 Mar; 169(3):925-9; discussion 929-30. PubMed ID: 12576814
[TBL] [Abstract][Full Text] [Related]
4. Instillation of bacillus Calmette-Guerin into the renal pelvis of a solitary kidney for the treatment of transitional cell carcinoma.
Ramsey JC; Soloway MS
J Urol; 1990 Jun; 143(6):1220-2. PubMed ID: 2342185
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guérin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract.
Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Nishimura K; Takaha N; Takahara S; Okuyama A
Eur Urol; 2000 Dec; 38(6):701-4;discussion 705. PubMed ID: 11111187
[TBL] [Abstract][Full Text] [Related]
6. [Kidney-conservative surgery followed by bacillus Calmette-Guerin instillation therapy for transitional cell carcinoma of solitary renal pelvis: a case report].
Ao T; Endo T; Shiokawa H; Shimura S; Adachi K; Koshiba K
Hinyokika Kiyo; 1993 May; 39(5):463-5. PubMed ID: 8322629
[TBL] [Abstract][Full Text] [Related]
7. 13-year experience with percutaneous management of upper tract transitional cell carcinoma.
Clark PE; Streem SB; Geisinger MA
J Urol; 1999 Mar; 161(3):772-5; discussion 775-6. PubMed ID: 10022682
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous management of renal pelvic tumors: a treatment option in selected cases.
Smith AD; Orihuela E; Crowley AR
J Urol; 1987 May; 137(5):852-6. PubMed ID: 3106652
[TBL] [Abstract][Full Text] [Related]
9. [Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract].
Okubo K; Ishitoya S; Maeda H; Suzuki Y; Arai Y
Nihon Hinyokika Gakkai Zasshi; 1997 Mar; 88(3):386-90. PubMed ID: 9125861
[TBL] [Abstract][Full Text] [Related]
10. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma.
Patel A; Fuchs GJ
J Urol; 1998 Jan; 159(1):71-5. PubMed ID: 9400440
[TBL] [Abstract][Full Text] [Related]
11. The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience.
Motamedinia P; Keheila M; Leavitt DA; Rastinehad AR; Okeke Z; Smith AD
J Endourol; 2016 Mar; 30(3):262-7. PubMed ID: 26630130
[TBL] [Abstract][Full Text] [Related]
12. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy?
Rastinehad AR; Ost MC; Vanderbrink BA; Greenberg KL; El-Hakim A; Marcovich R; Badlani GH; Smith AD
Urology; 2009 Jan; 73(1):27-31. PubMed ID: 18929398
[TBL] [Abstract][Full Text] [Related]
13. Durable response of a carcinoma in situ of the renal pelvis to topical bacillus Calmette-Guerin.
Herr HW
J Urol; 1985 Sep; 134(3):531-2. PubMed ID: 4032555
[TBL] [Abstract][Full Text] [Related]
14. The management of transitional cell carcinoma in solitary renal units.
Schoenberg MP; Van Arsdalen KN; Wein AJ
J Urol; 1991 Sep; 146(3):700-2; discussion 702-3. PubMed ID: 1875476
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
[TBL] [Abstract][Full Text] [Related]
16. Percutaneous management of transitional cell carcinoma of the renal collecting system: 9-year experience.
Jarrett TW; Sweetser PM; Weiss GH; Smith AD
J Urol; 1995 Nov; 154(5):1629-35. PubMed ID: 7563308
[TBL] [Abstract][Full Text] [Related]
17. 13-year survival comparison of percutaneous and open nephroureterectomy approaches for management of transitional cell carcinoma of renal collecting system: equivalent outcomes.
Lee BR; Jabbour ME; Marshall FF; Smith AD; Jarrett TW
J Endourol; 1999 May; 13(4):289-94. PubMed ID: 10405908
[TBL] [Abstract][Full Text] [Related]
18. Long-term effects of bacille Calmette-Guérin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract.
Hayashida Y; Nomata K; Noguchi M; Eguchi J; Koga S; Yamashita S; Hayashi M; Kanatake H
Urology; 2004 Jun; 63(6):1084-8. PubMed ID: 15183955
[TBL] [Abstract][Full Text] [Related]
19. Ureteroscopic resection of upper-tract transitional-cell carcinoma.
Ho KL; Chow GK
J Endourol; 2005 Sep; 19(7):841-8. PubMed ID: 16190841
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous therapy of low stage and grade urothelial neoplasia: long-term follow up.
Montanari E; Del Nero A; Bernardini P; Mangiarotti B; Confalonieri S; Grisotto M; Cordima G
Arch Ital Urol Androl; 2005 Dec; 77(4):211-4. PubMed ID: 16444935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
